Immunology and Biotherapies
21.5K views | +1 today
Follow
 
Scooped by Gilbert C FAURE
onto Immunology and Biotherapies
Scoop.it!

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent ... - MENAFN.COM

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent ...
MENAFN.COM
This is thefourth country to issue this patent as a result of the ExpeditedPatent Allowance Program which follows the issuance of U.S.
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Perinodal Adipose Tissue Participates in Immune Protection through a Lymphatic Vessel–Independent Route

Perinodal Adipose Tissue Participates in Immune Protection through a Lymphatic Vessel–Independent Route | Immunology and Biotherapies | Scoop.it
Lymphatic vessels remove and transport excess interstitial fluid to lymph nodes (LNs) for fluid balance and immune protection. LNs are typically surrounded by perinodal adipose tissue (PAT). However, PAT is a blood vessel–rich but lymphatic-rare tissue; therefore, how excess fluid in PAT is...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Oncopathology and Clinical Research | Peer Reviewed Journal

Oncopathology and Clinical Research | Peer Reviewed Journal | Immunology and Biotherapies | Scoop.it
Oncopathology and Clinical Research, home.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Fortress Biotech - Specializing in Acquiring, Developing and Commercializing Novel Pharmaceutical and Biotechnology Products

Fortress Biotech - Specializing in Acquiring, Developing and Commercializing Novel Pharmaceutical and Biotechnology Products | Immunology and Biotherapies | Scoop.it
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products....
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Frontiers | Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus | Microbiology

Frontiers | Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus | Microbiology | Immunology and Biotherapies | Scoop.it
The incidence of dengue virus (DENV) infections has been escalating in tropical and subtropical countries, but there are still no effective therapeutic options. In the present study, a DENV-1-specific human monoclonal antibody (HMAb), 1G5, isolated from single plasma cells obtained from the peripheral blood mononuclear cells of dengue patients was found to have potent neutralization activity against serotype 1 DENV (DENV-1). Its neutralization activity against DENV-2 was not as strong, and it was almost absent for DENV-3 and DENV-4. The results showed that HMAb 1G5 only binds to the envelop protein of intact DENV-1 or the envelop protein under unheated and non-reducing conditions, and that it does not bind to recombinant envelope protein. This could mean that the antibody recognizes a conformational epitope of the envelope protein. Further, the findings showed that HMAb 1G5 potently neutralizes DENV-1 in both the pre- and post-attachment phases of the virus at low concentrations. In vivo studies showed that HMAb 1G5 provides protection from DENV-1 infection in a murine model. In addition, antibody-dependent enhancement that occurs at lower doses of the antibody was completely abrogated by the introduction of Leu-to-Ala mutations (1G5-LALA) or deletion of nine amino acids (1G5-9del) in the Fc region. Therefore, HMAb 1G5 shows promise as a safe and effective agent for prophylactic and therapeutic treatment of DENV-1 infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Step right up: A biotech may soon sell an experimental med to dying ALS patients under ‘Right to Try’ – Endpoints News

Step right up: A biotech may soon sell an experimental med to dying ALS patients under ‘Right to Try’ – Endpoints News | Immunology and Biotherapies | Scoop.it
During the debate over the new Right to Try legislation, a number of critics raised the argument that some companies would try to cash in by selling experimental drugs with an undefined risk profile to desperate, dying patients.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo

Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo | Immunology and Biotherapies | Scoop.it
Article...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Personal cancer vaccines show positive results

Personal cancer vaccines show positive results | Immunology and Biotherapies | Scoop.it
Immunotherapies are moving to the forefront of cancer treatment. Recent clinical trials have demonstrated that these approaches can be personalized to the unique mutations profile of each individual's tumor, igniting new ...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) | Immunology and Biotherapies | Scoop.it
Abstract
CD19-specific chimeric antigen receptor (CAR) T cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. In 53 adult patients with ALL, we found a significant association of severe neurotoxicity with high pretreatment disease burden, higher peak CAR T cell expansion and early and higher elevations of proinflammatory cytokines in blood. Patients with severe neurotoxicity had evidence of blood-cerebrospinal fluid (CSF) barrier disruption correlating with neurotoxicity grade without association with CSF white blood cell count or CAR T-cell quantity in CSF. Proinflammatory cytokines were enriched in CSF during severe neurotoxicity with disproportionately high levels of IL6, IL8, MCP1 and IP10, suggesting central nervous system (CNS)-specific production. Seizures, seizure-like activity, myoclonus and neuroimaging characteristics suggested excitatory neurotoxicity, and we found elevated levels of endogenous excitatory agonists in CSF during neurotoxicity.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System | Immunology and Biotherapies | Scoop.it
Enhancing T cell responses against both viral and tumor Ags requires efficient costimulation and directed delivery of peptide Ags into APCs. Long peptide vaccines are considered favorable vaccine moieties from a clinical perspective, as they can harbor more than one immunogenic epitope enabling treatment of a broader target population. In addition, longer peptides are not extracellularly loaded on MHC class I; rather, they require intracellular processing and will thereby be presented to T cells mainly by professional APCs, thereby avoiding the risk of tolerance induction. The drawback of peptide vaccines regardless of peptide length is that naked peptides are not actively targeted to and taken up by APCs, and the standard nonconjugated adjuvant-peptide mixtures do not ensure cotargeting of the two to the same APC. We have identified a tetanus toxin–derived B cell epitope that can mediate the formation of immune complexes in the presence of circulating Abs. In this study, we show that these immune complexes improve both Ag uptake by APCs (blood monocytes and CD1c+ dendritic cells) and consequently improve CD8+ T cell recall responses in a human ex vivo blood loop system. The uptake of the peptide conjugate by blood monocytes is dependent on Abs and the complement component C1q. We envision that this strategy can be used to facilitate active uptake of Ags into APCs to improve T cell responses against pathogens or cancer.

This article is featured in In This Issue , p.[3][1]

[1]: /lookup/volpage/201/3
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

DSG2 Is a Functional Cell Surface Marker for Identification and Isolation of Human Pluripotent Stem Cells

DSG2 Is a Functional Cell Surface Marker for Identification and Isolation of Human Pluripotent Stem Cells | Immunology and Biotherapies | Scoop.it
DSG2 is a desmosomal cadherin molecule. In this article, Min and colleagues show that DSG2 is a valuable PSC surface marker that is essential for the maintenance of PSC self-renewal and pluripotency and the acquisition of pluripotency during somatic cell reprogramming through the regulation of...

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phas...

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phas... | Immunology and Biotherapies | Scoop.it
REGN3470-3471-3479 was well tolerated, displayed linear pharmacokinetics, and did
not lead to detectable immunogenicity. These data support further clinical development
of REGN3470-3471-3479 as a single-dose therapeutic drug for acute Ebola virus infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05‐09 antigen could be a malaria vaccine candidate

Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05‐09 antigen could be a malaria vaccine candidate | Immunology and Biotherapies | Scoop.it
Although it is generally agreed that an effective vaccine would greatly accelerate the control of malaria, the lone registered malaria vaccine Mosquirix™ has an efficacy of 30%‐60% that wanes rapidly, indicating a need for improved second‐generation ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Dendritic cells and routing cargo into exosomes - Leone - - Immunology and Cell Biology - Wiley Online Library

Abstract

Extracellular vesicles, released from cells, are important for intercellular communication. They are heterogeneous but fall into two broad categories based on origin and function: microvesicles formed by outward budding from the plasma membrane; and exosomes that originate as intraluminal vesicles in multivesicular endosomes that fuse with the plasma membrane to release them. Extracellular vesicles generally and exosomes in particular have powerful effects on specific immune responses, and recent advances highlight their potential therapeutic uses. Dendritic cells (DC) that have internalized antigen release exosomes that express MHC class II molecules loaded with antigenic peptides, co‐stimulatory molecules and intact antigen. Depending on the setting, these stimulate CD4 T‐cell proliferation either directly or only in the context of accessory antigen naïve DC. Here, we discuss the reasons for this; and review current knowledge about the loading of antigen, class II and other cargo into exosomes released by DC and other professional antigen‐presenting cells in the context of advances in exosome biology more generally.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Proliferation - Creative Diagnostics

Proliferation - Creative Diagnostics | Immunology and Biotherapies | Scoop.it
Creative Diagnostics is an innovative commercial company dedicated to offering high-quality products and services for the study of proliferation.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Viruses | Free Full-Text | Effect of Bacteriophage Infection in Combination with Tobramycin on the Emergence of Resistance in Escherichia coli and Pseudomonas aeruginosa Biofilms | HTML

Viruses | Free Full-Text | Effect of Bacteriophage Infection in Combination with Tobramycin on the Emergence of Resistance in Escherichia coli and Pseudomonas aeruginosa Biofilms | HTML | Immunology and Biotherapies | Scoop.it
Bacteriophage infection and antibiotics used individually to reduce biofilm mass often result in the emergence of significant levels of phage and antibiotic resistant cells. In contrast, combination therapy in Escherichia coli biofilms employing T4 phage and tobramycin resulted in greater than...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cellular Immunotherapy

Cellular Immunotherapy | Immunology and Biotherapies | Scoop.it
What if the cells that cancer affects could be trained to fight back? This is the core of cellular immunotherapy at Seattle Cancer Care Alliance (SCCA).
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Manufacturing a cell therapy peace-keeping force, and more

Manufacturing a cell therapy peace-keeping force, and more | Immunology and Biotherapies | Scoop.it
International Society for Stem Cell Research 2018 Annual Meeting: 2,500+ stem cell scientists from 50 countries will hear from 150+ speakers including: Fre...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform | Immunology and Biotherapies | Scoop.it
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Antibody Therapy and Its Expanding Role in Myeloma Treatment

Antibody Therapy and Its Expanding Role in Myeloma Treatment | Immunology and Biotherapies | Scoop.it
Join us for a FREE webinar designed to meet the educational needs of multiple myeloma patients and their caregivers. For patients with multiple myeloma and their caregivers, the fast-growing number of treatment options can be overwhelming. The importance of staying current on new developments in myeloma research and treatment has never been greater. Among the most exciting areas of myeloma research are treatments that work with a patient’s immune system to fight myeloma (immunotherapies). Currently, several antibody therapies (monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers [BiTEs]) are under study and are showing encouraging results. We invite you to join us for this webinar to learn about antibody therapy. This webinar takes a look at some of these new agents and discusses how they have performed in clinical trials. Myeloma patients and their caregivers are sure to find this information helpful as they make future treatment decisions with their care team. There is no fee for participating in this webinar. To register, please add this event to your cart and complete the required information on the checkout page.   If you are unable to register online or do not receive a confirmation email after registering (don't forget to check your spam folder), please contact our Registration Desk at 866-872-5840 (international callers please dial 617-502-2061). You can also contact us by ✉ email
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Can this cooler save kids from dying? | Bill Gates

Can this cooler save kids from dying? | Bill Gates | Immunology and Biotherapies | Scoop.it
Bill Gates shares two remarkable innovations that are helping deliver vaccines to the most remote places on earth.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

WELBIO - CEMIP, a new player in the acquired resistance to targeted therapies

WELBIO - CEMIP, a new player in the acquired resistance to targeted therapies | Immunology and Biotherapies | Scoop.it
WELBIO, Institut wallon virtuel de recherche d'excellence dans les domaines des sciences de la vie - Walloon Excellence in Lifesciences & BIOtechnology. Alain Chariot's team , WELBIO investigator at the University of Liège, shows that the CEMIP protein plays a role in resistance to...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge

A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge | Immunology and Biotherapies | Scoop.it
The HIV Env trimer exhibits a closed confirmation and restricts access to known antibody binding sites. Here the authors show that a small-molecule CD4-mimetic compound binds the HIV Env trimer and enhances antibody-mediated protection in a non-human primate model of infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association | Immunology and Biotherapies | Scoop.it

 bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rdCongress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina,Charleston, South Carolina.

 

All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbAT87Q –

– First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbAT87Q at 6 months –

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

KLRD1-expressing natural killer cells predict influenza susceptibility | Genome Medicine | Full Text

KLRD1-expressing natural killer cells predict influenza susceptibility | Genome Medicine | Full Text | Immunology and Biotherapies | Scoop.it
Influenza infects tens of millions of people every year in the USA. Other than notable risk groups, such as children and the elderly, it is difficult to predict what subpopulations are at higher risk of infection.
more...
No comment yet.